Etgar Levy‐Nissenbaum

5.6k citations

27 papers · 4.3k indexed · 2 hit papers · h-index 18

Molecular Biology top 5%
Biomaterials top 0.5%
Biomedical Engineering top 2%
Cardiology and Cardiovascular Medicine top 5%
Materials Chemistry top 10%

Co-authors: Omid C. Farokhzad Róbert Langer Frank Gu Liangfang Zhang Benjamin A. Teply Frank Alexis Sangyong Jon Vaishali Bagalkot
Topics: RNA Interference and Gene Delivery (7 papers)Advanced biosensing and bioanalysis techniques (7 papers)Nanoparticle-Based Drug Delivery (6 papers)
Cited by: Biomaterials Pharmaceutical Science Molecular Biology
Journals: Circulation Nature Genetics Nano Letters
Partner nations: Israel United States United Kingdom

In The Last Decade

Etgar Levy‐Nissenbaum

27 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Formulation of functionalized PLGA–PEG nanoparticles for in vivo targeted drug delivery

2006 1.0k citations Jianjun Cheng, Benjamin A. Teply et al. Biomaterials profile →
Quantum Dot−Aptamer Conjugates for Synchronous Cancer Imaging, Therapy, and Sensing of Drug Delivery Based on Bi-Fluorescence Resonance Energy Transfer

2007 751 citations Vaishali Bagalkot, Liangfang Zhang et al. Nano Letters profile →

Peers

Countries citing papers authored by Etgar Levy‐Nissenbaum

Since Specialization

Citations

This map shows the geographic impact of Etgar Levy‐Nissenbaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Etgar Levy‐Nissenbaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Etgar Levy‐Nissenbaum more than expected).

Fields of papers citing papers by Etgar Levy‐Nissenbaum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Etgar Levy‐Nissenbaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Etgar Levy‐Nissenbaum. The network helps show where Etgar Levy‐Nissenbaum may publish in the future.

Co-authorship network of co-authors of Etgar Levy‐Nissenbaum

This figure shows the co-authorship network connecting the top 25 collaborators of Etgar Levy‐Nissenbaum. A scholar is included among the top collaborators of Etgar Levy‐Nissenbaum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Etgar Levy‐Nissenbaum. Etgar Levy‐Nissenbaum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Hydrogel-forming microneedle arrays as a therapeutic option for transdermal esketamine delivery 2020 ·Journal of Controlled Release ·Aaron J. Courtenay,Emma McAlister,Maelíosa McCrudden,Lalitkumar K. Vora,Lilach Steiner,Galit Levin,Etgar Levy‐Nissenbaum,(unknown),Mary‐Carmel Kearney,Helen O. McCarthy,Ryan F. Donnelly	125
2	Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial 2016 ·Digestive Diseases and Sciences ·Iris Dotan,Etgar Levy‐Nissenbaum,Yehuda Chowers,Alexander Fich,Eran Israeli,Tomer Adar,(unknown),Hermona Soreq,Eran Goldin	10
3	Transepithelial Transport of Fc-Targeted Nanoparticles by the Neonatal Fc Receptor for Oral Delivery 2013 ·DSpace@MIT (Massachusetts Institute of Technology) ·Eric M. Pridgen,Frank Alexis,Timothy Kuo,Etgar Levy‐Nissenbaum,Rohit Karnik,Richard S. Blumberg,Róbert Langer,Omid C. Farokhzad	1
4	Pharmacokinetic and efficacy study of cisplatin and paclitaxel formulated in a new injectable poly(sebacic-co-ricinoleic acid) polymer 2012 ·European Journal of Pharmaceutics and Biopharmaceutics ·Etgar Levy‐Nissenbaum,Wahid Khan,Rajendra P. Pawar,Rinat Tabakman,(unknown),(unknown),(unknown),Leah N. Klapper,Abraham J. Domb	12
5	Engineering of Targeted Nanoparticles for Cancer Therapy Using Internalizing Aptamers Isolated by Cell-Uptake Selection 2012 ·ACS Nano ·Zeyu Xiao,Etgar Levy‐Nissenbaum,Frank Alexis,Andrej Lupták,Benjamin A. Teply,Juliana M. Chan,Jinjun Shi,(unknown),Judy W.M. Cheng,Róbert Langer,Omid C. Farokhzad	129
6	In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes 2009 ·PubMed ·Leonid Gaidukov,(unknown),Shiri Yacobson,(unknown),(unknown),Rinat Tabakman,Dan S. Tawfik,Etgar Levy‐Nissenbaum	35
7	HER‐2‐Targeted Nanoparticle–Affibody Bioconjugates for Cancer Therapy 2008 ·ChemMedChem ·Frank Alexis,Pamela A. Basto,Etgar Levy‐Nissenbaum,Aleksandar F. Radovic‐Moreno,Liangfang Zhang,Eric M. Pridgen,Andrew Z. Wang,(unknown),(unknown),Linda K. Molnar,Omid C. Farokhzad	117
8	Nanotechnology and aptamers: applications in drug delivery 2008 ·Trends in biotechnology ·Etgar Levy‐Nissenbaum,Aleksandar F. Radovic‐Moreno,Andrew Z. Wang,Róbert Langer,Omid C. Farokhzad	210
9	Quantum dot-aptamer conjugates for synchronous cancer imaging and therapy based on bi-fluorescence resonance energy transfer 2007 ·Clinical Cancer Research ·Liangfang Zhang,Vaishali Bagalkot,Etgar Levy‐Nissenbaum,Sangyong Jon,Róbert Langer,Omid C. Farokhzad	2
10	Targeted Aptamer-Nanoparticles to Diminish Drug Resistance of Cancer Cells in vitro Study 2007 ·TechConnect Briefs ·Frank Alexis,Pamela A. Basto,(unknown),Róbert Langer,Etgar Levy‐Nissenbaum	4
11	Targeted nanoparticles for cancer therapy 2007 ·Nano Today ·Frank Gu,Rohit Karnik,Andrew Z. Wang,Frank Alexis,Etgar Levy‐Nissenbaum,Seungpyo Hong,Róbert Langer,Omid C. Farokhzad	391
12	Quantum Dot−Aptamer Conjugates for Synchronous Cancer Imaging, Therapy, and Sensing of Drug Delivery Based on Bi-Fluorescence Resonance Energy Transferbreakdown → 2007 ·Nano Letters ·Vaishali Bagalkot,Liangfang Zhang,Etgar Levy‐Nissenbaum,Sangyong Jon,Philip W. Kantoff,Róbert Langer,Omid C. Farokhzad	751
13	Formulation of functionalized PLGA–PEG nanoparticles for in vivo targeted drug deliverybreakdown → 2006 ·Biomaterials ·Jianjun Cheng,Benjamin A. Teply,(unknown),Joseph J.�Y. Sung,Gaurav Luther,Frank Gu,Etgar Levy‐Nissenbaum,(unknown),Róbert Langer,Omid C. Farokhzad	1020
14	Confirmation of the association between male pattern baldness and the androgen receptor gene. 2006 ·PubMed ·Etgar Levy‐Nissenbaum,Michal Bar‐Natan,Moshe Frydman,Elon Pras	44
15	Clinical manifestations in Israeli cystinuria patients and molecular assessment of carrier rates in Libyan Jewish controls. 2003 ·PubMed ·(unknown),Etgar Levy‐Nissenbaum,Yitshak Kreiss,(unknown),(unknown)	7
16	Hypotrichosis simplex of the scalp is associated with nonsense mutations in CDSN encoding corneodesmosin 2003 ·Nature Genetics ·Etgar Levy‐Nissenbaum,Regina C. Betz,Moshe Frydman,Michel Simon,Hadas Lahat,(unknown),Boleslaw Goldman,Anette Bygum,(unknown),Axel M. Hillmer,Nathalie Jonca,Jaime Toribio,Roland Kruse,Georg Dewald,Sven Cichon,Christian Kubisch,Marina Guerrin,Guy Serre,Markus M. Nöthen,Elon Pras	108
17	Megalencephalic leukoencephalopathy with subcortical cysts; a founder effect in Israeli patients and a higher than expected carrier rate among Libyan Jews 2002 ·Human Genetics ·Bruria Ben‐Zeev,Etgar Levy‐Nissenbaum,Hadas Lahat,Yair Anikster,Yael Shinar,Nathan Brand,(unknown),Daune MacGregor,(unknown),Robert Kleta,Moshe Frydman,Elon Pras	27
18	A Missense Mutation in the LIM2 Gene Is Associated with Autosomal Recessive Presenile Cataract in an Inbred Iraqi Jewish Family 2002 ·The American Journal of Human Genetics ·Eran Pras,Etgar Levy‐Nissenbaum,(unknown),Hadas Lahat,Ehud I. Assia,(unknown),Moshe Frydman,Boleslaw Goldman,Elon Pras	92
19	Genetic Analysis of Brugada Syndrome in Israel: Two Novel Mutations and Possible Genetic Heterogeneity 2001 ·Genetic Testing ·Etgar Levy‐Nissenbaum,Michael Eldar,Qing Wang,Hadas Lahat,Bernard Belhassen,(unknown),Eitan Friedman,Elon Pras	13
20	A Missense Mutation in a Highly Conserved Region of CASQ2 Is Associated with Autosomal Recessive Catecholamine-Induced Polymorphic Ventricular Tachycardia in Bedouin Families from Israel 2001 ·The American Journal of Human Genetics ·Hadas Lahat,Elon Pras,(unknown),Nili Avidan,Edna Ben‐Asher,Orna Man,Etgar Levy‐Nissenbaum,(unknown),(unknown),(unknown),Doron Lancet,Michael Eldar	461

About Etgar Levy‐Nissenbaum

Etgar Levy‐Nissenbaum is a scholar working on Pharmaceutical Science, Biomaterials and Urology, having authored 27 papers that have together received 4.3k indexed citations. Recurring topics across this work include RNA Interference and Gene Delivery (7 papers), Advanced biosensing and bioanalysis techniques (7 papers) and Nanoparticle-Based Drug Delivery (6 papers). The work is most often cited by research in Biomaterials (1.4k citations), Pharmaceutical Science (581 citations) and Molecular Biology (2.3k citations). Etgar Levy‐Nissenbaum has collaborated with scholars based in Israel, United States and United Kingdom. Frequent co-authors include Omid C. Farokhzad, Róbert Langer, Frank Gu, Liangfang Zhang, Benjamin A. Teply, Frank Alexis, Sangyong Jon, Vaishali Bagalkot, Philip W. Kantoff and Jianjun Cheng. Their work appears in journals such as Circulation, Nature Genetics and Nano Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact